Experimental cell therapy tested for Tough-to-Treat blood cancer
NCT ID NCT06709131
Summary
This early-stage study is testing the safety and initial effectiveness of an experimental cell therapy called CT0991 in adults with acute myeloid leukemia (AML) that has returned or hasn't responded to previous treatments. The trial will enroll up to 24 participants to find the safest dose and see how their bodies respond to the treatment. Researchers will monitor for side effects and check if the therapy helps reduce or eliminate leukemia cells.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA(AML) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The first affiliated hospital of medical college of zhejiang university
Hangzhou, Zhejiang, 310003, China
Conditions
Explore the condition pages connected to this study.